<DOC>
	<DOCNO>NCT01595776</DOCNO>
	<brief_summary>Aim : value safety efficacy local intramuscular administration immunoselected autologous endothelial progenitor cell treatment critical limb ischemia patient without revascularization option . Primary goal : value feasibility mobilization , harvesting , immunoselection auto transplantation endothelial progenitor cell . Secondary goal : value efficacy local administration autologous endothelial progenitor cell treatment critical limb ischemia</brief_summary>
	<brief_title>Autologous Endothelial Progenitor Cells ( EPCs ) From Peripheral Blood Treatment Critical Limb Ischemia</brief_title>
	<detailed_description>Type study . Prospective single centre randomize . Aim study . To assess safety , feasibility efficacy local intramuscular administration autologous select CD 133+ cell patient suffer CLI . All patient enrol suffer CLI accord TASC 2 definition revascularization option , basis contrast CT angiography imaging . A detailed informed consent , approve EC , require . An age low 18 year upper 70 year poor marrow responsiveness drug simulation elderly people Clinical unsteadiness CLI , gangrene require major amputation poor life expectancy introduce exclusion criterion suppose latency EPCs action . Severe systemic illness judge increase risk marrow stimulation . Patients allergic diathesis , child-bearing age , previous EPCs muscular implant , previous medical experimental protocol conflict interest study exclude . Patients : enroll patient history Rutherford stage 4 ( rest pain ) 5 ( small ischemic lesion ) PAD . All patient previous ( contrast CT , MR angiography ) vascular image exclude revascularization option , endovascular open encounter enrolment exclusion criterion . Every patient undergo routine physical instrumental examination include electrocardiogram , chest X-ray blood sample analysis . Younger patient meet Buerger disease criterion , whereas others pure atherosclerotic lesion . CEUS Imaging Protocol . Two operator ( F.C . A.G. , 20 3 year experience , respectively ) blind treatment perform contrast-enhanced US patient . Two US scanner ( Philips iU22 ( Bothell , WA , USA ) linear array L9-3 transducer GE Logiq e9 ( GE Healthcare , Milwaukee , WI , USA ) linear array L6-9 transducer use . The image parameter : reduce transmit power ( mechanical index &lt; 0.06 ) , approximately 7-10 frame per second one focus well level target ensure uniform pressure field . Dual-mode presentation grayscale image side-by-side contrast image facilitate real-time identification anatomic structure ROI selection . Image loop approximately 60 second acquire . Effort make uniform gain across image avoid gain saturation . The TGC ( time gain compensation ) set contrast arrival uniform black image show . A vial contrast agent ( SonoVue BR1 ; Bracco , Milan , Italy ) prepare concentration 2x108 sulfur hexafluoride-filled microbubbles per milliliter , accord manufacturer 's recommendation . Prior injection , microbubbles resuspend shake vial . The position probe record patient order maintain position follow . The contrast injection consist intravenous bolus 4.8 ml contrast agent inject antecubital vein 2 second follow saline flush 5 ml . The injection make patient supine 10 minute rest avoid exercise relate micro-vascular dilatation . The radiologist maintain constant image plane aid tissue ( fundamental image ) `` Contrast Side/Side '' image mode . Image analysis . The image loop transfer personal computer analysis . The main image analysis task : ) identification tibialis anterior artery ( TAA ) area , b ) selection representative region normal tibialis anterior muscle ( TAM ) c ) formulation time-intensity curve . Two manually defined region interest ( ROI ) , 2 cm 4 cm sided-squares , place , respectively , tibialis anterior muscle evidence arterial branch , tibialis anterior artery small tibialis arterial branch . The ROIs place anatomical position patient avoid unwanted difference follow examination . A time/intensity curve ( TIC ) obtain ROI . From analysis CEUS time-intensity curve , compute regional blood flow ( RBF ) volume ( RBV ) . Time-intensity curve extract use commercial quantification software ( QontraXt v.3.60 , AMID , Rome , Italy ) . This software allow manual region interest ( ROI ) selection , measurement select ROI area provide linear data time-intensity curve . For ROI normal ATM effort make place region area without large vessel . The ROI ATA 2 cm square area ATM ROI 4 cm square area . Time-intensity curve obtain compute mean intensity pixel comprise within ROI time point . For image loop calculate : - RBV consist total amount contrast medium within select ROI , period time . Due characteristic US contrast medium , reflect quantity blood define region . It directly related area curve ( AUC ) . - RBF direct ratio perfusion give ROI . It consist Contrast Media flow ( related Blood Flow ) select ROI . It related Mean Transit Time . Marrow stimulation . Human recombinant granulocyte colony-stimulating factor ( rhGCSF ) administer subcutaneously 4-5 consecutive day dosage 10 µg/kg daily , split 2 dos . Starting third day mobilization , CD133+ cell count monitor daily cytofluorimetric analysis 2 ml sample obtain patient ' peripheral blood . The minimum CD133+ cell count acceptable leukapheresis ( LKF ) collection 10/µl . Patients monitor G-CSF related side effect . Leukapheresis collection . A single LKF collection plan patient use third generation cell separator device ( Spectra Cobe , Lakewood , CO ) , process least 2.5 blood volume accord internal protocol stem cell collection . Patients monitor blood pressure heart rate entire collection procedure . Immediately LKF sample patient 's peripheral blood take haemocytometric analysis evaluate platelet count Hb level . Each leukapheresis collection dilute 10 % acide citrate dextrose ( ACD-A ) maintain overnight 4°C immunomagnetic cell selection . A sample 2 ml LKF bag take cytofluorimetric analysis . Four hour LKF collection coagulation parameter , electrolyte level hemocytometric analysis evaluate . Immunomagnetic cell selection . CD133 immunomagnetic cell selection perform day LKF collection use Clini-MACS ( Miltenyi Biotec ) device accord manufacturer 's standard protocol . Briefly , CliniMACS CD133 reagent ( form super paramagnetic particle compose iron oxide dextran conjugate murine monoclonal antibody ) add cell incubation . The product subsequently wash dilution buffer ( CliniMACS PBS-EDTA buffer supplement 0.5 % human serum albumin ) cell bag hung device automate selection CD133 label cell . A sample 2 ml positive fraction take cytofluorimetric analysis . Quality control . Clonogenic assay . A sample take CD133 cell positive fraction immunomagnetic cell selection procedure seed short term ( 14 day ) clonogenic assay . A standard mixture methylcellulose plus recombinant human erythropoietin , rh stem cell factor ( SCF ) , rhGM-CSF , rh interleukin-3 ( IL-3 ) employed ( Stem Cell Technologies , Vancouver , BC , Canada ; MACS Media , Miltenyi Biotec GmbH , Bergisch Gladbach , Germany ) . Microbial culture . Microbial culture immunoselection waste bag contain negative fraction carry detect aerobic-anaerobic bacteria fungal contamination . A sample 10ml inoculated culture medium ( Bact/Alert FA BacT/Alert FN , Organon Teknika Corp. , Durham , NC ) incubate 10 day 37°C . Cytofluorimetric analysis . Samples obtain peripheral blood mobilization G-CSF , time leukapheresis immunomagnetic cell selection analyze flow cytometry evaluate expression specific stem cell endothelial antigen . Becton Dickinson FACSCanto employ flow cytometric assay lyse no-wash technique , use follow monoclonal antibody : anti-CD45 fluorescein isothiocyanate ( FITC ) ( Becton Dickinson , San Jose , CA ) , anti-CD34 Peridinin-chlorophyll-protein complex ( PerCP ) ( 8G12 clone , Becton Dickinson ) , anti-CD133 phycoerythrin ( PE ) ( AC133 clone , Miltenyi Biotec ) anti-VEGF-R2 allophycocyanin ( APC ) ( R &amp; D system ) . Whole blood process follow instruction VEGF-R2 ( KDR ) determination . Each blood sample transfer 50 ml falcon tube bring total volume 30 ml add ammonium phosphate contain lysis buffer ( Becton Dickinson ) . After lysis period 5 minute PB centrifuge 500g 5 minute wash two time PBS contain 0,5 % bovine serum albumin ( BSA ) . 100 µl sample transfer BD tube cytometric analysis incubate 15 minute 1µg/105 cell IgG order block nonspecific site . 50 µl IgG block sample incubate 20 µl anti-VEGF-R2 antibody 30 minute 4°C dark wash twice PBS . At end last wash step , 10 µl antibody ( anti-CD45 , anti-CD34 , anti-CD133 ) add incubated 10 minute room temperature dark . Each sample acquire BD FACSCanto record 100.000 event inside lymphocyte plus monocyte gate . Data file analyze FACS Diva 6.1 software . Viability assess use 7-amino-actinomycin D ( 7-AAD ) ( Molecular Probes , Eugene , OR ) . A sample Hill EBM2 clonogenic assay take patient 's peripheral blood mobilization ( time LKF collection ) . Implant procedure . After loco-regional anesthesia knee cutaneous disinfection , 45-48 ml autologous CD133+ saline solution suspension administer intramuscularly 1 ml deep injection 18G needle . The injection allocate : 10 ml anterior compartment leg , 10 ml superficial posterior compartment , 10 ml deep posterior compartment , 10 ml lateral compartment remain part foot . Baseline assessment follow . Pain assessment carry personal scale 3 degree ( mild , moderate severe ) pain kill drug use monitoring . Ischemic lesion treat weekly wound management skilled nurse . Preoperative 3 , 6 12 month implant assess CEUS , lesion evolution pain management .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Inclusion criterion : 1. age &gt; 18 year 2. write informed consent 3. critical limb ischemia ( TASC 2 criterion ) 4 . No surgical endovascular option Exclusion criterion : 1. clinical instability 2. extensive gangrene 3. every serious systemic disease 4. life expectancy &lt; 24 month 5. previous similar study 6. previous experimental drug study within 3 month 7. allergy 8. child bearing age 9. conflict interest study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>CLI , PAD , Buerger disease</keyword>
</DOC>